Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
or

Moleculin Biotech CS (MBRX)

Moleculin Biotech CS (MBRX)
1.4100 -0.3600 (-20.34%) 16:09 ET [NASDAQ]
1.4000 x 20,500 1.4100 x 11,300
Realtime by (Cboe BZX)
1.4000 x 20,500 1.4100 x 11,300
Realtime - - (-) -
Quote Overview for Thu, Feb 20th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
1.4000
Day High
1.7600
Open 1.6800
Previous Close 1.7700 1.7700
Volume 3,516,345 3,516,345
Avg Vol 13,479,395 13,479,395
Stochastic %K 40.25% 40.25%
Weighted Alpha -82.44 -82.44
5-Day Change +1.0100 (+240.48%) +1.0100 (+240.48%)
52-Week Range 0.3975 - 10.3500 0.3975 - 10.3500
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,356
  • Shares Outstanding, K 4,156
  • Annual Sales, $ 0 K
  • Annual Income, $ -29,770 K
  • EBIT $ -29 M
  • EBITDA $ -29 M
  • 60-Month Beta 1.94
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.73

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -1.25
  • Number of Estimates 1
  • High Estimate -1.25
  • Low Estimate -1.25
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.13%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3975 +259.75%
on 02/12/25
Period Open: 1.8800
3.6499 -60.82%
on 02/13/25
-0.4500 (-23.94%)
since 01/17/25
3-Month
0.3975 +259.75%
on 02/12/25
Period Open: 2.6700
3.6499 -60.82%
on 02/13/25
-1.2400 (-46.44%)
since 11/20/24
52-Week
0.3975 +259.75%
on 02/12/25
Period Open: 7.4970
10.3500 -86.18%
on 03/11/24
-6.0670 (-80.93%)
since 02/20/24

Most Recent Stories

More News
Top 5 Biotech Stocks That Got Most Retail Buzz Last Week

From merger updates to earnings surprises, these healthcare stocks saw the biggest spike in Stocktwits chatter.

GRAL : 51.87 (-1.39%)
ADMA : 16.07 (+0.03%)
EXEL : 35.08 (+0.03%)
GLYC : 0.2778 (-10.65%)
MBRX : 1.4100 (-20.34%)
JTC Team Announces Presenting Company Line Up for the Virtual Investor “Ask the CEO” Conference Being Held October 24-25, 2023

- Live video webcast interactive Q&A with participating companies -

AREC : 0.5742 (-2.26%)
CNSP : 0.0735 (-12.29%)
EVFM : 0.0092 (-1.08%)
XBIO : 4.03 (-1.95%)
PALI : 0.9650 (-1.17%)
NVNO : 3.83 (+6.69%)
GRI : 0.4352 (-17.90%)
MBRX : 1.4100 (-20.34%)
Moleculin to Participate in the Virtual Investor Ask the CEO Conference

/PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug...

MBRX : 1.4100 (-20.34%)
Moleculin Doses First Subjects in Phase 2 Portion of Clinical Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML)

/PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a growing pipeline, including...

MBRX : 1.4100 (-20.34%)
Moleculin Announces Completion of Enrollment in U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB107)

/PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a growing pipeline, including...

MBRX : 1.4100 (-20.34%)
Moleculin Announces New Positive Independent Report of No Cardiotoxicity in Annamycin

/PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a growing pipeline,...

MBRX : 1.4100 (-20.34%)
Moleculin Announces Abstract Accepted for Poster Presentation at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting

/PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a growing pipeline,...

MBRX : 1.4100 (-20.34%)
Moleculin to Present at the H.C. Wainwright 25th Annual Global Investment Conference

/PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a growing pipeline,...

MBRX : 1.4100 (-20.34%)
Moleculin Reports Second Quarter 2023 Financial Results

/PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a growing pipeline,...

MBRX : 1.4100 (-20.34%)
Moleculin Provides Update on Ongoing Clinical Trials and Outlines Expected Upcoming Milestones

– Announces successful completion of the Phase 1B portion of its Phase 1B/2 clinical trial Annamycin in combination with Cytarabine for the treatment of AML...

MBRX : 1.4100 (-20.34%)

Business Summary

Moleculin Biotech, Inc. is a preclinical and clinical-stage pharmaceutical company which focused on the development of anti-cancer drug candidates. The company's lead product candidate is Annamycin, a Phase II clinical stage anthracycline for the treatment of relapsed or refractory acute myeloid leukemia....

See More

Key Turning Points

3rd Resistance Point 2.7200
2nd Resistance Point 2.4700
1st Resistance Point 2.1200
Last Price 1.4100
1st Support Level 1.5200
2nd Support Level 1.2700
3rd Support Level 0.9200

See More

52-Week High 10.3500
Fibonacci 61.8% 6.5481
Fibonacci 50% 5.3738
Fibonacci 38.2% 4.1994
Last Price 1.4100
52-Week Low 0.3975

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

Mastering Fibonacci: The Hidden Order in Market Movements